{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:04:19Z","timestamp":1788026659140,"version":"build-2784847793"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>The function of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9), a novel plasma protein, has mainly been involved in cholesterol metabolism in the liver, while, more interestingly, recent data have shown that PCSK9 also took part in the modulation of inflammation, which appeared to be another explanation for the reduction of cardiovascular risk by PCSK9 inhibition besides its significant effect on lowering lower-density lipoprotein cholesterol (LDL-C) concentration. Overall, a series of previous studies suggested an association of PCSK9 with inflammation. Firstly, PCSK9 is able to induce the secretion of proinflammatory cytokines in macrophages and in other various tissues and elevated serum PCSK9 levels could be observed in pro-inflammatory conditions, such as sepsis, acute coronary syndrome (ACS). Secondly, detailed signaling pathway studies indicated that PCSK9 positively regulated toll-like receptor 4 expression and inflammatory cytokines expression followed by nuclear factor-kappa B (NF-kB) activation, together with apoptosis and autophagy progression. Besides, PCSK9 enhanced and interacted with scavenger receptors (SRs) of inflammatory mediators like lectin-like oxidized-LDL receptor-1 (LOX-1) to promote inflammatory response. Additionally, several studies also suggested that the role of PCSK9 in atherogenesis was intertwined with inflammation and the interacting effect shown between PCSK9 and LOX-1 was involved in the inflammatory response of atherosclerosis. Finally, emerging clinical trials indicated that PCSK9 inhibitors could reduce more events in patients with ACS accompanied by increased inflammatory status, which might be involved in its attenuating impact on arterial plaque. Hence, further understanding of the relationship between PCSK9 and inflammation would be necessary to help prevent and manage the atherosclerotic cardiovascular disease (ASCVD) clinically. This review article will update the recent advances in the link of PCSK9 with inflammation.<\/jats:p>","DOI":"10.3389\/fcvm.2022.763516","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T05:23:54Z","timestamp":1645161834000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Proprotein Convertase Subtilisin\/Kexin Type 9 and Inflammation: An Updated Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Na-Qiong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrcardio.2016.185","article-title":"Inflammatory processes in cardiovascular disease: a route to targeted therapies","volume":"14","author":"Ruparelia","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jacl.2014.07.001","article-title":"Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease","volume":"8","author":"Zhang","year":"2014","journal-title":"J Clin Lipidol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijcard.2016.04.103","article-title":"Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort study","volume":"215","author":"Xie","year":"2016","journal-title":"Int J Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"152786","DOI":"10.1155\/2013\/152786","article-title":"LOX-1, OxLDL, and atherosclerosis","volume":"2013","author":"Pirillo","year":"2013","journal-title":"Mediators Inflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","article-title":"PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement","volume":"253","author":"Ferri","year":"2016","journal-title":"Atherosclerosis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.atherosclerosis.2014.04.001","article-title":"Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease","volume":"234","author":"Li","year":"2014","journal-title":"Atherosclerosis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of PCSK9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2016","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5551\/jat.RV17003","article-title":"PCSK9 and atherosclerosis - lipids and beyond","volume":"24","author":"Shapiro","year":"2017","journal-title":"J Atheroscler Thromb."},{"key":"B9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/infdis\/jix574","article-title":"Role of PCSK9 in the development of mouse periodontitis before and after treatment: a double-edged sword","volume":"217","author":"Sun","year":"2018","journal-title":"J Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/path.4630","article-title":"Local effects of human PCSK9 on the atherosclerotic lesion","volume":"238","author":"Giunzioni","year":"2016","journal-title":"J Pathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3109\/07853890.2015.1042908","article-title":"Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease","volume":"47","author":"Li","year":"2015","journal-title":"Ann Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"piie00842","DOI":"10.1128\/IAI.00842-19","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) is not induced in artificial human inflammation and is not correlated with inflammatory response","volume":"88","author":"Heinzl","year":"2020","journal-title":"Infect Immun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/cvr\/cvw053","article-title":"Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms","volume":"110","author":"Tavori","year":"2016","journal-title":"Cardiovasc Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1194\/jlr.M078360","article-title":"PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction","volume":"59","author":"Sun","year":"2018","journal-title":"J Lipid Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1194\/jlr.M051326","article-title":"Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin","volume":"55","author":"Kuhnast","year":"2014","journal-title":"J Lipid Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/01.HYP.0000130484.20501.df","article-title":"C-reactive protein: risk marker or mediator in atherothrombosis?","volume":"44","author":"Jialal","year":"2004","journal-title":"Hypertension"},{"key":"B18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Emerging Risk Factors","year":"2010","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jacc.2018.12.075","article-title":"Vascular inflammation in subclinical atherosclerosis detected by hybrid PET\/MRI","volume":"73","author":"Fernandez-Friera","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11010-014-2259-0","article-title":"Lipopolysaccharide augments the uptake of oxidized LDL by up-regulating lectin-like oxidized LDL receptor-1 in macrophages","volume":"400","author":"Hossain","year":"2015","journal-title":"Mol Cell Biochem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"20963","DOI":"10.1074\/jbc.272.34.20963","article-title":"Low density lipoprotein oxidation and its pathobiological significance","volume":"272","author":"Steinberg","year":"1997","journal-title":"J Biol Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1016\/j.ijcard.2013.07.113","article-title":"High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy","volume":"168","author":"Koenig","year":"2013","journal-title":"Int J Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1348913","DOI":"10.1155\/2020\/1348913","article-title":"PCSK9 expression in epicardial adipose tissue: molecular association with local tissue inflammation","volume":"2020","author":"Dozio","year":"2020","journal-title":"Mediators Inflamm."},{"key":"B25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased Plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J Innate Immun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study","volume":"248","author":"Cheng","year":"2016","journal-title":"Atherosclerosis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e106294","DOI":"10.1371\/journal.pone.0106294","article-title":"Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies","volume":"9","author":"Almontashiri","year":"2014","journal-title":"PLoS ONE."},{"key":"B29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1093\/cvr\/cvaa254","article-title":"PCSK9 and LRP5 in macrophage lipid internalization and inflammation","volume":"117","author":"Badimon","year":"2021","journal-title":"Cardiovasc Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.bbrc.2017.02.085","article-title":"PCSK9 regulates the chemokine receptor CCR2 on monocytes","volume":"485","author":"Grune","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/cvr\/cvn311","article-title":"Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice","volume":"81","author":"Guo","year":"2009","journal-title":"Cardiovasc Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0123685","DOI":"10.1371\/journal.pone.0123685","article-title":"TLR4\/NF-kappaB signaling contributes to chronic unpredictable mild stress-induced atherosclerosis in ApoE-\/- mice","volume":"10","author":"Tang","year":"2015","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/01.ATV.0000160340.72641.87","article-title":"Nuclear factor kappaB signaling in atherogenesis","volume":"25","author":"de Winther","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","article-title":"Inflammation stimulates the expression of PCSK9","volume":"374","author":"Feingold","year":"2008","journal-title":"Biochem Biophys Res Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","article-title":"Signaling to NF-kappaB by Toll-like receptors","volume":"13","author":"Kawai","year":"2007","journal-title":"Trends Mol Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","article-title":"Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis","volume":"46","author":"Dwivedi","year":"2016","journal-title":"Shock."},{"key":"B40","doi-asserted-by":"publisher","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci Transl Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1093\/eurheartj\/eht532","article-title":"Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo","volume":"35","author":"Akhmedov","year":"2014","journal-title":"Eur Heart J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/j.jacc.2017.04.010","article-title":"LOX-1 in atherosclerosis and myocardial ischemia: biology, genetics, and modulation","volume":"69","author":"Pothineni","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1161\/CIRCRESAHA.107.149724","article-title":"Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet","volume":"100","author":"Mehta","year":"2007","journal-title":"Circ Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages","volume":"30","author":"Tang","year":"2012","journal-title":"Int J Mol Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/107424840200700304","article-title":"Oxidized low-density lipoprotein receptor LOX-1 and apoptosis in human atherosclerotic lesions","volume":"7","author":"Li","year":"2002","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1093\/cvr\/cvz262","article-title":"Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines","volume":"116","author":"Liu","year":"2020","journal-title":"Cardiovasc Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1089\/ars.2014.6054","article-title":"Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta","volume":"22","author":"Ding","year":"2015","journal-title":"Antioxid Redox Signal."},{"key":"B48","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/ars.2016.6631","article-title":"Cross-Talk between PCSK9 and damaged mtDNA in vascular smooth muscle cells: role in apoptosis","volume":"25","author":"Ding","year":"2016","journal-title":"Antioxid Redox Signal."},{"key":"B49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cardiores.2004.08.007","article-title":"Vascular NADPH oxidases: molecular mechanisms of activation","volume":"65","author":"Brandes","year":"2005","journal-title":"Cardiovasc Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.jcmg.2019.09.024","article-title":"Long-Term administration of proprotein convertase subtilisin\/kexin type 9 inhibitors reduces arterial FDG uptake","volume":"12","author":"Vlachopoulos","year":"2019","journal-title":"JACC Cardiovasc Imaging."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Bernelot Moens","year":"2017","journal-title":"Eur Heart J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e016263","DOI":"10.1161\/JAHA.120.016263","article-title":"Evolocumab, a PCSK9-monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia","volume":"9","author":"Leucker","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","article-title":"Effect of alirocumab on mortality after acute coronary syndromes","volume":"140","author":"Steg","year":"2019","journal-title":"Circulation."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.jcmg.2019.06.022","article-title":"PCSK9 antibody alirocumab attenuates arterial wall inflammation without changes in circulating inflammatory markers","volume":"12","author":"Hoogeveen","year":"2019","journal-title":"JACC Cardiovasc Imaging."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","article-title":"Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR study)","volume":"119","author":"Baruch","year":"2017","journal-title":"Am J Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.763516\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T05:23:56Z","timestamp":1645161836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.763516\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":57,"alternative-id":["10.3389\/fcvm.2022.763516"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.763516","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"article-number":"763516"}}